GlassScriptPhysician profile
Adeyemi Adebanji Ogunleye
NPI 1366763096
$4,316.26
in general payments reported to CMS, 2019-2025
10 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,410 · 2020: $68.43 · 2021: $487 · 2022: $55.52 · 2023: $52.92 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,651.30 | 2019 | |
| Medical Device Business Services, INC. | $903.15 | 2019 | |
| Integra Lifesciences Corporation | $607.66 | 2019-2021 | |
| Tei Biosciences INC | $339.70 | 2019 | |
| Mentor Worldwide LLC | $205.81 | 2022-2025 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Davol INC. | $195.82 | 2021 | |
| Sientra, INC. | $165.84 | 2021 | |
| Abbvie INC. | $116.69 | 2023-2025 | |
| Checkpoint Surgical, INC | $102.15 | 2020-2021 | |
| Baxter Healthcare | $28.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeyemi Ogunleye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.